Join
Live feed
·
PRReleasevia Quantisnow
Exelixis Inc. logo

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024

ByQuantisnow·Wall Street's wire, on your screen.
EXEL· Exelixis Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EXEL (Exelixis Inc.) and more on Quantisnow.